Cochrane · systematic review · CD011571
Antistreptococcal interventions for guttate and chronic plaque psoriasis
Dupire, G, Droitcourt, C, Hughes, C, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
6
No studies
18
Included studies
NR
No studies 18 · 72%Ungraded 1 · 4%Very low 6 · 24%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Penicillin compared to no treatment for guttate psoriasis
Population: guttate psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 Penicillin vs no treatment | no estimate extracted | NR | No studies |
Proportion of participants with adverse events and severe adverse events Penicillin vs no treatment | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) Penicillin vs no treatment | RR 2 [0.68, 5.85] | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants achieving PASI 75 or PGA 1 to 2 Penicillin vs no treatment | no estimate extracted | NR | No studies |
Risk of having at least one relapse at long‐term Penicillin vs no treatment | no estimate extracted | NR | No studies |
Erythromycin compared to no treatment for guttate psoriasis
Population: guttate psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 Erythromycin vs no treatment | no estimate extracted | NR | No studies |
Proportion of participants with adverse events and severe adverse events Erythromycin vs no treatment | no estimate extracted | NR | No studies |
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) Erythromycin vs no treatment | no estimate extracted | NR | No studies |
Proportion of participants achieving PASI 75 or PGA 1 to 2 Erythromycin vs no treatment | no estimate extracted | NR | No studies |
Risk of having at least one relapse at long‐term Erythromycin vs no treatment | no estimate extracted | NR | No studies |
Azithromycin compared to vitamin C for chronic plaque psoriasis
Population: chronic plaque psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 Azithromycin vs vitamin C | no estimate extracted | NR | No studies |
Proportion of participants with adverse events and severe adverse events Azithromycin vs vitamin C | no estimate extracted | 1 study · 50 participants | Ungraded |
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) Azithromycin vs vitamin C | no estimate extracted | NR | No studies |
Proportion of participants achieving PASI 75 or PGA 1 to 2 Azithromycin vs vitamin C | RR 25.06 [1.6, 393.59] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Risk of having at least one relapse at long‐term Azithromycin vs vitamin C | no estimate extracted | NR | No studies |
Rifampicin compared to placebo for guttate psoriasis
Population: guttate psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 Rifampicin vs placebo | no estimate extracted | NR | No studies |
Proportion of participants with adverse events and severe adverse events Rifampicin vs placebo | no estimate extracted | NR | No studies |
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) Rifampicin vs placebo | no estimate extracted | NR | No studies |
Proportion of participants achieving PASI 75 or PGA 1 to 2 Rifampicin vs placebo | no estimate extracted | NR | No studies |
Risk of having at least one relapse at long‐term Rifampicin vs placebo | no estimate extracted | NR | No studies |
Tonsillectomy compared to no intervention for chronic plaque psoriasis
Population: chronic plaque psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 Tonsillectomy vs no intervention | no estimate extracted | NR | No studies |
Proportion of participants with adverse events and severe adverse events Tonsillectomy vs no intervention | RR 2.81 [0.12, 63.83] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) Tonsillectomy vs no intervention | RR 2.81 [0.12, 63.83] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants achieving PASI 75 or PGA 1 to 2 Tonsillectomy vs no intervention | RR 6.56 [0.37, 116.7] | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision |
Risk of having at least one relapse at long‐term Tonsillectomy vs no intervention | no estimate extracted | NR | No studies |